C WorldWide Group Holding A S Purchases 46,004 Shares of Royalty Pharma PLC $RPRX

C WorldWide Group Holding A S raised its position in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 7.0% in the fourth quarter, HoldingsChannel reports. The fund owned 700,461 shares of the biopharmaceutical company’s stock after acquiring an additional 46,004 shares during the period. Royalty Pharma accounts for approximately 0.5% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 28th largest holding. C WorldWide Group Holding A S’s holdings in Royalty Pharma were worth $27,066,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Private Trust Co. NA boosted its holdings in shares of Royalty Pharma by 52.9% during the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 288 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 790 shares during the period. Larson Financial Group LLC boosted its stake in shares of Royalty Pharma by 31.9% in the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 306 shares during the period. Richardson Financial Services Inc. bought a new stake in shares of Royalty Pharma in the third quarter valued at approximately $54,000. Finally, Fifth Third Bancorp boosted its stake in shares of Royalty Pharma by 16.9% in the third quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 362 shares during the period. Institutional investors own 54.35% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on RPRX shares. TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday, February 27th. Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, May 1st. Citigroup boosted their price target on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, UBS Group boosted their price target on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $53.71.

Royalty Pharma Price Performance

Shares of RPRX opened at $50.79 on Monday. Royalty Pharma PLC has a one year low of $32.15 and a one year high of $51.65. The company has a market cap of $29.30 billion, a P/E ratio of 34.55, a P/E/G ratio of 1.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The firm has a 50 day simple moving average of $47.62 and a two-hundred day simple moving average of $42.75.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The business had revenue of $631.00 million during the quarter, compared to the consensus estimate of $881.69 million. Research analysts forecast that Royalty Pharma PLC will post 5.04 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a yield of 1.9%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s payout ratio is currently 63.95%.

Insider Buying and Selling

In other news, CFO Terrance P. Coyne sold 34,791 shares of the company’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 139,164 shares of company stock worth $6,624,902 in the last three months. 18.84% of the stock is owned by insiders.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.